Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Aug;78(4):508–510. doi: 10.1038/bjc.1998.523

The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.

C Crawley 1, P Ross 1, A Norman 1, A Hill 1, D Cunningham 1
PMCID: PMC2063096  PMID: 9716035

Abstract

The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma. Data on all patients with small bowel malignancy who were seen at a single institution over a 5-year period were retrieved from the gastrointestinal unit and hospital databases, and these cases were reviewed. Eight patients with advanced small bowel adenocarcinoma received PVI 5FU-based chemotherapy. The overall response rate in assessable patients was 37.5% (3/8). The median overall survival was 13 months (range 1-28), and progression-free survival was 7.8 months (range 0-15). Overall, the treatment was well tolerated and symptomatic benefit was seen. In conclusion, PVI 5-FU has activity in this disease. This should be assessed either as a single agent or as part of a combination regimen such as epirubicin/cisplatin/PVI FU (ECF) in a multicentre randomized study.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bamias A., Hill M. E., Cunningham D., Norman A. R., Ahmed F. Y., Webb A., Watson M., Hill A. S., Nicolson M. C., O'Brien M. E. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival. Cancer. 1996 May 15;77(10):1978–1985. doi: 10.1002/(SICI)1097-0142(19960515)77:10<1978::AID-CNCR3>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  2. Coia L., Hoffman J., Scher R., Weese J., Solin L., Weiner L., Eisenberg B., Paul A., Hanks G. Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161–167. doi: 10.1016/0360-3016(94)90531-2. [DOI] [PubMed] [Google Scholar]
  3. Delcore R., Thomas J. H., Forster J., Hermreck A. S. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993 Dec;166(6):626–631. doi: 10.1016/s0002-9610(05)80668-3. [DOI] [PubMed] [Google Scholar]
  4. Jigyasu D., Bedikian A. Y., Stroehlein J. R. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer. 1984 Jan 1;53(1):23–25. doi: 10.1002/1097-0142(19840101)53:1<23::aid-cncr2820530106>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  5. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  6. Ohkusa T., Ohtomo K., Yamamoto N., Fujimoto H. Primary adenocarcinoma of duodenal bulb benefitted by chemotherapy. Dig Dis Sci. 1991 Nov;36(11):1653–1656. doi: 10.1007/BF01296412. [DOI] [PubMed] [Google Scholar]
  7. Ouriel K., Adams J. T. Adenocarcinoma of the small intestine. Am J Surg. 1984 Jan;147(1):66–71. doi: 10.1016/0002-9610(84)90036-9. [DOI] [PubMed] [Google Scholar]
  8. Rotman N., Pezet D., Fagniez P. L., Cherqui D., Celicout B., Lointier P. Adenocarcinoma of the duodenum: factors influencing survival. French Association for Surgical Research. Br J Surg. 1994 Jan;81(1):83–85. doi: 10.1002/bjs.1800810128. [DOI] [PubMed] [Google Scholar]
  9. Sakker S., Ware C. C. Carcinoma of the duodenum: comparison of surgery, radiotherapy, and chemotherapy. Br J Surg. 1973 Nov;60(11):867–872. doi: 10.1002/bjs.1800601108. [DOI] [PubMed] [Google Scholar]
  10. Webb A., Cunningham D., Scarffe J. H., Harper P., Norman A., Joffe J. K., Hughes M., Mansi J., Findlay M., Hill A. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol. 1997 Jan;15(1):261–267. doi: 10.1200/JCO.1997.15.1.261. [DOI] [PubMed] [Google Scholar]
  11. Yeung R. S., Weese J. L., Hoffman J. P., Solin L. J., Paul A. R., Engstrom P. F., Litwin S., Kowalyshyn M. J., Eisenberg B. L. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer. 1993 Oct 1;72(7):2124–2133. doi: 10.1002/1097-0142(19931001)72:7<2124::aid-cncr2820720711>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES